Aldeyra Therapeutics Inc
NASDAQ:ALDX
Aldeyra Therapeutics Inc
Aldeyra Therapeutics, Inc. operates as a biotechnology company. The company is headquartered in Lexington, Massachusetts and currently employs 12 full-time employees. The company went IPO on 2014-05-02. The firm's lead product candidate, reproxalap, is a treatment in late-stage development for dry eye disease (DED) and allergic conjunctivitis (AC). The company has additional product candidates in development for proliferative vitreoretinopathy (PVR), primary vitreoretinal lymphoma (PVRL) and other retinal diseases, autoimmune disease, and cancer. The firm's product development pipeline is focused on immune-mediated ocular diseases and select systemic diseases and encompasses two biological mechanisms of action: reactive aldehyde species (RASP) modulation and dihydrofolate reductase inhibition. The immunological activity of its product candidates generally leads to diminished levels of pathological inflammation through down-regulation of immune cell activation or proliferation.
Aldeyra Therapeutics, Inc. operates as a biotechnology company. The company is headquartered in Lexington, Massachusetts and currently employs 12 full-time employees. The company went IPO on 2014-05-02. The firm's lead product candidate, reproxalap, is a treatment in late-stage development for dry eye disease (DED) and allergic conjunctivitis (AC). The company has additional product candidates in development for proliferative vitreoretinopathy (PVR), primary vitreoretinal lymphoma (PVRL) and other retinal diseases, autoimmune disease, and cancer. The firm's product development pipeline is focused on immune-mediated ocular diseases and select systemic diseases and encompasses two biological mechanisms of action: reactive aldehyde species (RASP) modulation and dihydrofolate reductase inhibition. The immunological activity of its product candidates generally leads to diminished levels of pathological inflammation through down-regulation of immune cell activation or proliferation.
Clinical Progress: Aldeyra achieved FDA acceptance of two new drug applications—Reproxalap for dry eye disease and ADX-2191 for primary vitreoretinal lymphoma, the latter receiving priority review.
Pipeline Expansion: The company is advancing next-generation RASP modulators (ADX-629, ADX-246, ADX-248), with multiple Phase 2 and planned Phase 1/2 trials across systemic and ocular diseases.
Financial Position: Aldeyra reported $174.3 million in cash, cash equivalents, and marketable securities at year-end 2022, projecting runway into the second half of 2024 with funding for potential product launches.
Reproxalap Differentiation: The 12-month safety study for Reproxalap showed a statistically significant 37% improvement in visual acuity over vehicle, a result not typically seen in dry eye studies.
Commercialization Readiness: Preparations are underway for U.S. launches of Reproxalap and ADX-2191, with robust partnering discussions ongoing for Reproxalap.
Key Catalysts Ahead: Several major clinical milestones are expected in 2023, including trial results for allergic conjunctivitis, chronic cough, and retinitis pigmentosa.
